The three common alleles at the APOE locus influence the onset and lifetime risk of typical late-onset Alzheimer's disease (AD). Other loci may also alter risk of late-onset AD. One may assess the relative influence of APOE on the genetic contribution to AD by estimating the proportion of AD heritab
A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease
β Scribed by Charles B. Hall; Richard B. Lipton; Martin Sliwinski; Walter F. Stewart
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 146 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
β¦ Synopsis
Dementia is characterized by accelerated cognitive decline before and after diagnosis as compared to normal ageing. Determining the time at which that rate of decline begins to accelerate in persons who will develop dementia is important both in describing the natural history of the disease process and in identifying the optimal time window for which treatments might be useful. We model that time at which the rate of decline begins to accelerate in persons who develop dementia relative to those who do not by using a change point in a mixed linear model. A proΓΏle likelihood method is proposed to draw inferences about the change point. The method is applied to data from the Bronx Ageing Study, a cohort study of 488 initially non-demented community-dwelling elderly individuals who have been examined at approximately 12-month intervals over 15 years. Cognitive function was measured using the Buschke Selective Reminding test, a memory test with high reliability and known discriminative validity for detecting dementia. We found that the rate of cognitive decline as measured by this test in this cohort increases on average 5.1 years before the diagnosis of dementia.
π SIMILAR VOLUMES
## Abstract We performed linkage analysis for age at onset (AAO) in the total Alzheimer's disease (AD) NIMH sample (Nβ=β437 families). Families were subset as lateβonset (320 families, AAO β₯65) and early/mixed (117 families, at least 1 member with 50< AAO <65). Treating AAO as a censored trait, we